"10.1371_journal.pone.0052995","plos one","2012-12-28T00:00:00Z","Sarah C Mutka; Lucia H Green; Evie L Verderber; Jane P Richards; Doug L Looker; Elizabeth A Chlipala; Gary J Rosenthal","N30 Pharmaceuticals, Inc., Boulder, Colorado, United States of America; Premier Laboratory, LLC, Longmont, Colorado, United States of America","Conceived and designed the experiments: SCM JPR DLL GJR. Performed the experiments: SCM LHG ELV EAC. Analyzed the data: SCM LHG ELV JPR EAC GJR. Contributed reagents/materials/analysis tools: EAC. Wrote the paper: SCM GJR.","All authors except Elizabeth Chlipala are or were employees of N30 Pharmaceuticals, the funder of this study. Elizabeth Chlipala (Premier Laboratory) was paid to perform the immunohistochemistry work reported in this manuscript. N30 Pharma is developing a novel class of disease modifying therapies that preserve intracellular GSNO (Snitrosoglutathione), a key regulator of organ repair, regeneration, and healing. There are no further patents, products in development or marketed products relevant to this paper to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","12","Sarah C Mutka","SCM",7,TRUE,4,4,6,2,TRUE,TRUE,FALSE,0,NA,FALSE
